Abstract
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effective immune responses and subsequently virus clearance. Development of potent HBsAg secretion inhibitors would provide a better insight into HBV immunopathogenesis and therapy. Investigating new non-toxic HBsAg secretion inhibitors targeting either viral or cellular factors could restore the immune response to remove virally infected hepatocytes after inhibiting SVPs. In this study, we overview several classes of HBV inhibitors with focus on their limitations and advantages over anti-HBsAg secretion potential.
Highlights
Hepatitis B virus as a member of the Hepadnaviridae family is responsible for acute and chronic hepatitis in humans
In that study, which was conducted to produce anti-hepatitis B virus (HBV) agents to inhibit HBV, it was observed that Cs derivates are potent to prevent viral entry through Na+-taurocholate co-transporting polypeptide (NTCP) pathway (Shimura et al, 2017)
HBV surface antigen (HBsAg) targeted small interfering RNAs (siRNAs) have been evaluated in a novel NMRI animal model of HBV infection in order to suppress the antigen production (Klein et al, 2003)
Summary
Hepatitis B virus as a member of the Hepadnaviridae family is responsible for acute and chronic hepatitis in humans. HBsAg secretion has shown to be inhibited in both HBV integrated and transient transfected HepG2 cell lines as high as 70% and 90%, respectively. Similar HBsAg secretion inhibition has been observed in a cell line infected with HBV expressing NTCP after NJK14047 treatment (Kim et al, 2017).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
